Israel To Become First In World To Test Oravax Oral COVID-19 Vaccine

The gift of the Jews. It’s safe to say that vax skeptics would be less averse to a pill.

Quick note: Tech giants are shutting us down. You know this. Twitter, LinkedIn, Google Adsense, Pinterest permanently banned us. Facebook, Google search et al have shadow-banned, suspended and deleted us from your news feeds. They are disappearing us. But we are here. We will not waver. We will not tire. We will not falter, and we will not fail. Freedom will prevail.

Subscribe to Geller Report newsletter here — it’s free and it’s critical NOW when informed decision making and opinion is essential to America's survival. Share our posts on your social channels and with your email contacts. Fight the great fight.

Follow me on Gettr. I am there, click here. It's open and free.

Remember, YOU make the work possible. If you can, please contribute to Geller Report.

Israel to become first in world to test Oravax oral COVID-19 vaccine

Oravax Medical is gearing up to commence clinical trials at Tel Aviv Sourasky Medical Center.

By Mayan Jeffe-Hoffman, Jerusalem Post, JULY 22, 2021 20:29

Israel is about to become the first country in the world to test the oral COVID-19 vaccine developed by Oramed Pharmaceuticals, the company’s CEO Nadav Kidron told The Jerusalem Post.
Oramed’s subsidiary, Oravax Medical, is gearing up to commence clinical trials of its vaccine at Sourasky Medical Center in Tel Aviv after receiving approval for its study protocol from the hospital’s Institutional Review Board. It is now waiting for approval from the Health Ministry, which is expected within a few weeks.
Oravax already completed GMP manufacturing in Europe of several thousand capsules that would be available for the Israeli trial and eventually in other countries.

Oramed is a clinical-stage pharmaceutical company based on technology developed by Jerusalem’s Hadassah-University Medical Center. In March, it announced a joint venture with India-based Premas Biotech to develop a novel oral vaccine. Together they formed Oravax. The vaccine is based on Oramed’s “POD” oral delivery technology and Premas’s vaccine technology.
Oramed’s technology can be used to orally administer a number of protein-based therapies, which would otherwise be delivered by injection. Oramed is in the midst of a Phase III clinical trial through the US Food and Drug Administration of an oral insulin capsule for Type 1 and Type 2 diabetes.

Premas has been working on developing a vaccine against the novel coronavirus since March.

The new Oravax vaccine candidate targets three structural proteins of the novel coronavirus, as opposed to the single spike protein targeted by the current Moderna and Pfizer vaccines, Kidron said.
As such, “this vaccine should be much more resistant to COVID-19 variants,” he said. “Even if the virus gets through one line, there is a second line, and if through the second line, there is a third.”

The vaccine is being tested in preclinical studies against COVID-19 variants, including the Delta one.

The company completed a pilot animal study and found that the vaccine promoted the development of Immunoglobulin G (IgG) antibodies and Immunoglobulin A (IgA). IgA is necessary for longer-term immunity.

The protocol for the inaugural Phase I/II trial that the company hopes to move forward with at Sourasky would involve 24 volunteers who have not yet been inoculated with another vaccine. Half of the group would take one capsule, and the other half would take two, Kidron said, adding that there is no placebo group because the goal is to measure the level of antibodies and other immunity indicators.

“The idea here is that we want to show proof of concept: that it works for people,” he said. “I pray and hope that we will. Imagine that we could give someone an oral vaccine and they are vaccinated. This would be a revolution for the entire world.”
With proof of the concept, “the whole world opens up,” Kidron said.

“An oral COVID-19 vaccine would eliminate several barriers to rapid, wide-scale distribution, potentially enabling people to take the vaccine themselves at home,” he told the Post. “While ease of administration is critical today to accelerate inoculation rates, an oral vaccine could become even more valuable in the case that a COVID-19 vaccine may be recommended annually like the standard flu shot.”

The advantages of an oral vaccine go beyond safety and efficacy because oral medications tend to have fewer side effects, Kidron said.
The vaccine can be shipped at refrigerator temperatures and even stored at room temperature, “making it logistically easier to get it anywhere around the world,” he added.

Finally, an oral vaccine would not require professional administration.

The Phase I/II trial is expected to take around six weeks from the time of recruitment.

If the trial is successful, Kidron said he plans to put the vaccine on an accelerated ro
ad to receive emergency-use approval in the countries that need it most, such as those in South America that have not been able to acquire enough vaccines to inoculate their populations.

The company would hold its Phase III trial with a limited number of volunteers and look for first approval in one of these “emerging markets,” Kidron said, and only later seek US Food and Drug Administration authorization.
“Israel and the US and some of the other richer countries were the first to get Pfizer and Moderna,” he said. “But it looks to me like the people behind in the race will take over by being the first ones to get the oral vaccine.”

Have a tip we should know? Your anonymity is NEVER compromised. Email tips@thegellerreport.com

The Truth Must be Told

Your contribution supports independent journalism

Please take a moment to consider this. Now, more than ever, people are reading Geller Report for news they won't get anywhere else. But advertising revenues have all but disappeared. Google Adsense is the online advertising monopoly and they have banned us. Social media giants like Facebook and Twitter have blocked and shadow-banned our accounts. But we won't put up a paywall. Because never has the free world needed independent journalism more.

Everyone who reads our reporting knows the Geller Report covers the news the media won't. We cannot do our ground-breaking report without your support. We must continue to report on the global jihad and the left's war on freedom. Our readers’ contributions make that possible.

Geller Report's independent, investigative journalism takes a lot of time, money and hard work to produce. But we do it because we believe our work is critical in the fight for freedom and because it is your fight, too.

Please contribute here.


Make a monthly commitment to support The Geller Report – choose the option that suits you best.

Pin It on Pinterest